Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,416,520
  • Shares Outstanding, K 62,292
  • Annual Sales, $ 27,120 K
  • Annual Income, $ -239,560 K
  • EBIT $ -180 M
  • EBITDA $ -167 M
  • 60-Month Beta 0.59
  • Price/Sales 58.53
  • Price/Cash Flow N/A
  • Price/Book 6.11

Options Overview Details

View History
  • Implied Volatility 99.60% (-4.18%)
  • Historical Volatility 212.65%
  • IV Percentile 56%
  • IV Rank 23.55%
  • IV High 257.62% on 09/19/25
  • IV Low 50.92% on 02/05/25
  • Expected Move (DTE 14) 2.26 (10.60%)
  • Put/Call Vol Ratio 0.70
  • Today's Volume 7,424
  • Volume Avg (30-Day) 9,891
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 169,530
  • Open Int (30-Day) 187,546
  • Expected Range 19.07 to 23.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.93
  • Number of Estimates 5
  • High Estimate -0.75
  • Low Estimate -1.05
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +38.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.55 +3.80%
on 12/05/25
31.43 -32.13%
on 11/11/25
-4.73 (-18.15%)
since 11/05/25
3-Month
13.65 +56.26%
on 09/23/25
71.50 -70.17%
on 10/28/25
+3.38 (+18.83%)
since 09/05/25
52-Week
6.62 +222.21%
on 12/06/24
71.50 -70.17%
on 10/28/25
+14.74 (+223.67%)
since 12/05/24

Most Recent Stories

More News
Stocks Settle Mixed on Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.10%....

PATH : 18.67 (+1.03%)
DG : 132.37 (+5.65%)
HRL : 24.34 (+0.75%)
TXN : 182.54 (+1.34%)
$IUXX : 25,692.05 (+0.43%)
SAIC : 100.61 (-1.16%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-165s (-0.18%)
COST : 894.68 (-0.13%)
FIVE : 173.20 (+2.84%)
ESZ25 : 6,878.25s (+0.17%)
GFS : 38.95 (+3.65%)
Stocks Pressured as Bond Yields Rise and Chip Stocks Fall

The S&P 500 Index ($SPX ) (SPY ) is down by -0.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.28%. December E-mini S&P futures...

PATH : 18.67 (+1.03%)
DG : 132.37 (+5.65%)
HRL : 24.34 (+0.75%)
BF.B : 30.40 (+3.16%)
$IUXX : 25,692.05 (+0.43%)
SAIC : 100.61 (-1.16%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-165s (-0.18%)
COST : 894.68 (-0.13%)
ESZ25 : 6,878.25s (+0.17%)
GFS : 38.95 (+3.65%)
LRCX : 158.70 (+1.02%)
Stocks Pressured by Higher Bond Yields and Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) is down up by -0.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.38%. December E-mini S&P...

MSTR : 178.99 (-3.77%)
PATH : 18.67 (+1.03%)
DG : 132.37 (+5.65%)
HRL : 24.34 (+0.75%)
GLXY : 25.51 (-7.47%)
BF.B : 30.40 (+3.16%)
$IUXX : 25,692.05 (+0.43%)
COIN : 269.73 (-1.58%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-165s (-0.18%)
FIVE : 173.20 (+2.84%)
ESZ25 : 6,878.25s (+0.17%)
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

QURE : 21.33 (-6.20%)
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Nov. 28, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws...

QURE : 21.33 (-6.20%)
QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Nov. 22, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws...

QURE : 21.33 (-6.20%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to...

QURE : 21.33 (-6.20%)
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

LOS ANGELES , Nov. 14, 2025 /PRNewswire/ --  The DJS Law Group  announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE...

QURE : 21.33 (-6.20%)
uniQURE N.V. Investigation: Investors Encouraged to Contact Kirby McInerney LLP

The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQURE N.V. (“uniQURE” or the “Company”) (NASDAQ:QURE) investors concerning the Company’s...

QURE : 21.33 (-6.20%)
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm

LOS ANGELES , Nov. 11, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V....

QURE : 21.33 (-6.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 25.12
2nd Resistance Point 24.05
1st Resistance Point 22.69
Last Price 21.33
1st Support Level 20.26
2nd Support Level 19.19
3rd Support Level 17.83

See More

52-Week High 71.50
Fibonacci 61.8% 46.72
Fibonacci 50% 39.06
Fibonacci 38.2% 31.40
Last Price 21.33
52-Week Low 6.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar